Riskpilot← Back to searchSign inGet full accessOmnitrx ApS
APSActiveCVR 29782911Haldor Topsøes Allé 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 2006— employeeswww.omnitrx.com
Revenue 2025
DKK -11K
-2% vs 2024
EBITDA margin
100.0%
+2% vs 2024
Equity ratio
97.7%
Financial strength
Net profit 2025
DKK -59K
-314% vs 2024
| Revenue | DKK -11K | -2% |
| EBITDA | DKK -11K | +2% |
| Net profit | DKK -59K | -314% |
| Total assets | DKK 739K | -38% |
| Equity | DKK 722K | -8% |
| Employees | — | — |
Legal name
Omnitrx ApS
CVR number
29782911
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
5. oktober 2006
Share capital
DKK 749.770
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede direktion.
Company purpose
Selskabets formål er udvikling, produktion og kommercialisering af elektronik samt enhver i forbindelse hermed beslægtet virksomhed
Address
Haldor Topsøes Allé 1
Phone
+4527113480
Email
tgn@qrios.dk
Website
www.omnitrx.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27 | 43 | 37 | 91 | -973 | 912 | -647 | 1.927 | 1.940 | 4.681 | -24 | -21 | -11 | -11 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 27 | 43 | 37 | 91 | -6 | 912 | -647 | 1.927 | 1.940 | 4.681 | -24 | -21 | -11 | -11 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 27 | 43 | 37 | 91 | -6 | 912 | -647 | 1.927 | 1.940 | 4.681 | -24 | -21 | -11 | -11 |
| Net financials | 534 | 365 | 1.056 | 1.799 | -858 | 1.028 | -524 | 2.031 | 1.769 | 4.665 | -77 | 3.649 | 47 | -49 |
| Profit before tax | 531 | 361 | 1.032 | 1.792 | -864 | 1.021 | -530 | 2.024 | 1.762 | 4.658 | -101 | 3.628 | 35 | -60 |
| Tax | 133 | 97 | 268 | 422 | -188 | 225 | 5 | 450 | 392 | 1.032 | -22 | 798 | 8 | -1 |
| Net profit | 397 | 264 | 764 | 1.370 | -676 | 796 | -535 | 1.574 | 1.370 | 3.625 | -78 | 2.830 | 28 | -59 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 5.801 | 5.785 | 6.677 | 8.449 | 8.274 | 9.025 | 8.419 | 10.383 | 10.259 | 14.687 | 13.671 | 16.361 | 1.194 | 739 |
| Equity | 5.618 | 5.774 | 6.400 | 7.769 | 6.951 | 7.600 | 6.914 | 8.334 | 9.547 | 13.011 | 12.723 | 15.553 | 781 | 722 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 183 | 11 | 277 | 680 | 1.323 | 1.425 | 1.505 | 2.049 | 712 | 1.676 | 948 | 808 | 413 | 17 |
| Total debt | 183 | 11 | 277 | 680 | 1.323 | 1.425 | 1.505 | 2.049 | 712 | 1.676 | 948 | 808 | 413 | 17 |
EBITDA margin
-1115000.0%
This company
15.8%
Market median
-7057062% vs market
20122025
Equity ratio
97.7%
This company
38.2%
Market median
+156% vs market
20122025
Return on equity
-8.2%
This company
18.4%
Market median
-145% vs market
20122025
Net profit margin
-5907000.0%
This company
8.1%
Market median
-72926026% vs market
20122025
Asset turnover
-0.02×
This company
1.12×
Market median
-102% vs market
20122025
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TB Founder | Founder | 2006 | — | — |
TG Chief Executive Officer | Chief Executive Officer | 2007 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Vaulten ApS | Company | 66.7% | 100.0% | 2021 |
Omnitrx ApS | Company | 20.0% | 20.0% | 2011 |
MODA DENT ApS | Company | 50.0% | 50.0% | 2011 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Vaulten ApS
Omnitrx ApS Board members of Omnitrx ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tina Brix Andersen | Founder | 0 companies |
| Thomas Gerner Nørgaard | Chief Executive Officer | 0 companies |